[Effects of low-molecular-weight heparin on proliferative glomerulonephritis].
To investigate the effects of LMWH on proliferative nephritis, we randomized 41 patients who had obvious mesangial cell proliferation testified by renal biopsy into 2 groups according to age, course, clinical manifestations and the pathological lesions. The patients in the control group were given steroid, cyclophosphamide and bennazipril, and the patients in the treated group LMWH (fraxiparin) with the dosage of 60 anti Xa IU.kg-1.day-1 besides the medicine used in the control group. We observed a significant decrease in proteinuria and increase in serum albumin in the treated group compared with those in the control group after 4 weeks of treatment (P < 0.05). The improvement of creatinine clearance in the treated group was significant after 8 and 12 weeks treatment compared with that in the control group (P < 0.05). Our data indicated that LMWH can decrease the proteinuria in the patients who have intraglomerular coagulation and proliferative nephritis with various degrees of sclerosis, and it is helpful to relieve nephrotic syndrome. Because the less risk of hemorrhage, LMWH can be used for long-term treatment to prevent glomerulosclerosis and the process of renal function loss without special mornitoring.